Description
Mefloquine Tablet
Mefloquine Hydrochloride Tablets IP / BP / USP (250 mg)
Frontline Long-Acting Schizontocidal Antimalarial & Chemoprophylaxis
Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a leading Indian manufacturer, CDMO partner, and wholesale exporter of advanced anti-infective, tropical medicine, and travel health therapeutics. We manufacture ultra-high-purity, structurally stable Mefloquine Hydrochloride Tablets (250 mg) within our WHO–GMP certified, high-capacity solid dosage manufacturing facilities.
This essential public health commodity serves as a critical strategic export to national defense ministries, travel immunization clinics, international relief procurement channels, and digital B2B wholesale marketplaces across Sub-Saharan Africa, the CIS, LATAM, and South-East Asia.
Product Overview
This formulation operates as an “Intra-Erythrocytic Food Vacuole Disrupter.” It ensures clinical efficacy by targeting the asexual blood stages of malaria parasites, physically halting their ability to digest host hemoglobin and causing rapid cellular autolysis.
Mechanism 1 (Blood Schizontocidal Elimination): Mefloquine physically enters infected red blood cells and concentrates within the acidic food vacuole of the Plasmodium falciparum and Plasmodium vivax merozoites.
Mechanism 2 (Hemoglobin Digestion Blockade): Once inside, it chemically complexes with membrane lipids and disrupts the parasite’s food vacuole integrity. This physically arrests the polymerization of toxic free heme into inert hemozoin crystals, causing the parasite to choke on its own metabolic waste.
Mechanism 3 (Extended Plasma Half-Life Kinetics): Mefloquine exhibits an exceptionally long therapeutic half-life (14 to 21 days). This long-acting kinetic profile allows it to maintain a continuous chemical shield in the bloodstream, making it highly effective for once-weekly preventative dosing.
Product Composition & Configuration
We supply Mefloquine Hydrochloride in the internationally standardized strength calibrated for both adult therapeutic clearance and weekly travel prophylaxis.
| Active Ingredient Monograph | Calibrated Strength | Formulation Delivery Matrix | Primary Clinical Application |
| Mefloquine Hydrochloride IP / BP / USP | 250 mg
(Equivalent to 228 mg Mefloquine Base) | Oral Solid Uncoated Tablet (Cross-scored for exact pediatric dividing) | Dual-Mode Antimalarial: High-dose 3-day treatment for active clearance, or low-dose once-weekly regimen for traveler chemoprophylaxis. |
| Excipients | Pharma Grade | Microcrystalline Cellulose, Lactose, Magnesium Stearate | The Disintegration Core: Engineered for uniform mechanical compression and rapid disintegration. |
Technical & Logistics Specifications
HS Code: 3004.90.99 (Medicaments acting on parasitic diseases / Anti-malarials)
CAS Number: 51773-92-3 (Mefloquine Hydrochloride) / 53230-10-7 (Mefloquine Base)
Dosage Form: Oral Solid Tablet
Packaging Configurations:
Traveler Prophylaxis Packs: 4 or 8 Tablets per Blister Strip packed in high-barrier Alu-Alu (Cold-Form Foil) strips (calibrated for a 1-to-2 month travel cycle).
Institutional Tenders: Bulk packs of 100 / 500 Tablets per induction-sealed HDPE bottle for public health deployment. Our tropicalized packaging matrices completely block environmental moisture transit, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.
Advanced Manufacturing Integrity & Quality Controls
Micro-Dose Cross-Contamination Barriers: Because multi-drug anti-infective processing demands zero active compound carryover, our tableting lines execute compression inside Dedicated HVAC-Isolated Negative-Pressure Production Blocks, completely satisfying rigid international B2B regulatory audits.
Geometric Particle Blending Accuracy: Mefloquine raw powders can exhibit variations in flowability during processing. We deploy Automated High-Speed Forced-Feeder Compression Matrices, physically ensuring absolute weight uniformity and perfect chemical content distribution across every single tablet.
In-Vitro Dissolution Profiling: Every production batch physically undergoes rigid Automated Dissolution Profiling, chemically validating that our generic solid doses precisely match the rapid kinetic disintegration and bioequivalence curves of global innovator benchmarks (such as Lariam).
Primary Indications
Travel Medicine & Chemoprophylaxis: Prevention of Malaria in international travelers, military personnel, and expatriates migrating into endemic regions presenting a high risk of chloroquine-resistant Plasmodium falciparum strains.
Tropical Emergency Medicine: Treatment of mild-to-moderate, uncomplicated acute malaria infections caused by P. falciparum or P. vivax.
Usage Instructions
The Chemoprophylaxis Weekly Protocol: For malaria prevention, the standard dose is one 250 mg tablet taken physically once a week. The regimen must begin 2 weeks prior to entering the endemic zone, continue weekly throughout the stay, and extend for 4 consecutive weeks after leaving the region to chemically clear late-maturing liver merozoites.
The Post-Meal Administration Directive: Swallow the tablet physically whole with a full glass of water. It is physically critical to take this medication with or immediately after a heavy meal to maximize its systemic absorption and reduce gastrointestinal side effects.
Vomiting Redose Rule: If a patient vomits within 30 minutes of therapeutic oral administration, the entire dose must be repeated immediately. If vomiting occurs between 30 and 60 minutes, a half-dose must be re-administered.
Safety Warning: POTENT LONG-ACTING ANTI-MALARIAL. For Professional Medical Supervision Only. Neuropsychiatric Risk Warning: May chemically interact with central nervous system pathways; physically monitor for acute psychiatric symptoms including severe anxiety, depression, restlessness, confusion, hallucinations, or vivid nightmares. Halt Prophylaxis: If neurological symptoms occur during preventative use, stop the medication immediately and switch to an alternative chemical class. Seizure Danger: Use with extreme caution in patients with a history of epilepsy. Contraindications: Absolute contraindications in patients presenting with active depression, generalized anxiety disorder, schizophrenia, severe psychiatric history, suicidal ideation, severe hepatic impairment, or known hypersensitivity to quinoline derivatives.
Global CDMO Services & Wholesale Supply Chain
Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated Third-Party Contract Manufacturing (CDMO Services) and bulk private-label export pipelines for generic Mefloquine Hydrochloride 250 mg Tablets. Whether you are executing a procurement contract for a National Ministry of Defense Travel Tender, supplying an international humanitarian NGO relief network, or maintaining active inventory listings on an international digital B2B Pharmaceutical Marketplace across Africa, Southeast Asia, or LATAM, we deliver all required documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Stability Testing Matrix Sheets, and Complete CTD Format Dossier sets) for rapid entry registration.
Commercial & Bulk Procurement Inquiries:
Corporate Head Office: Mumbai, Maharashtra, India
Primary Manufacturing Base: Boisar, Maharashtra, India
WhatsApp / Direct Call: +91 7710003340
Corporate Email: info@healthyinc.co.in
